Cancer biologics refer to a substance used in the prevention, detection, or treatment of cancer and other disorders that is created from a living creature or its byproducts. Immunoglobulins, interleukins, and vaccinations are examples of biologic agents. A form of cancer treatment known as "biological therapy" employs the body's immune system to eradicate cancer cells. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and others, and is distributed through various channels such as hospitals, clinics, and others. The cancer biologics market research report is one of a series of new reports from The Business Research Company that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer biologics market grew from $86.64 billion in 2022 to $96.33 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer biologics market is expected to grow from $140.88 billion in 2027 at a CAGR of 10.0%. The rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market's growth. Chronic disorders are diseases that persist over a long period and hinder the health of people with disabilities, and cancer is one of the most common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to the World Health Organization (WHO), in 2020, chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over the coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion, as they are proteins that are quickly digested and inactivated if given by mouth, so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis, and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates, but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers that help physicians decide the treatments for their patients by utilising physiological biomarkers for predicting performance. Predictive biomarkers study tumour growth in patients by analysing the major etiological factors, as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the most cost-effective treatment regimens, especially for the biologics based on gene therapy. According to the FDA approval process for new cancer treatments and biological products, the application for approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company-sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from several alternative sources. In May 2020, Boehringer Ingelheim, a Germany-based, research-driven pharmaceutical company, acquired Northern Biologics for an undisclosed amount. This acquisition would provide Boehringer Ingelheim with two additional assets to add to its existing cancer immunology portfolio that complement Northern Biologics' current offerings, supporting the company's goal to target "cold" tumours with synergistic combination methods. The acquisition includes Northern Biologics’ preclinical cancer antibody pipeline, which is expanding its immuno-oncology portfolio. Northern Biologics is a Canada-based clinical-stage biotechnology company. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co., Inc., Novartis, and Pfizer. North America was the largest region in the cancer biologics market in 2022. The Middle East is expected to be the fastest growing region in the global cancer biologics market during the forecast period. The regions covered in the global cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Other Types 2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications 3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer diagnostics market size will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cancer diagnostics market size is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd., GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2022. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

Tumor ablation therapy devices are minimally invasive devices used in the treatment of tumors, commonly of kidney, liver and lung. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. The tumor ablation therapy devices market research report is one of a series of new reports from The Business Research Company that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tumor ablation therapy devices market grew from $0.56 billion in 2022 to $0.64 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor ablation therapy devices market is expected to grow from $1.1 billion in 2027 at a CAGR of 14.4%. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, COVIDien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc. was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In August 2022, Imagin Medical, a Canada-based urologic oncology company acquired enCAGE Coil™ Precision Ablation System for Prostate Cancer from TROD Medical NV for $2.5m. The acquisition would strengthen Imagin’s position as a urologic oncology company and expand its portfolio in the field of prostate cancer. TROD Medical NV is a Belgium-based medical device company. Major players in the tumor ablation therapy devices market are Galil Medical Inc., Misonix Inc., HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic PLC., EDAP TMS S.A, Neuwave Medical Inc., BVM Medical Limited, and Erbe Elektromedizin GmbH. North America was the largest region in the tumor ablation therapy devices market in 2022. Asia-Pacific was the second largest region in the global tumor ablation therapy devices market. The regions covered in the global tumor ablation therapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tumor ablation therapy devices market is segmented - 1) By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Technologies 2) By Treatment: Surgical, Laparoscopic, Percutaneous 3) By End User: Hospitals, Oncology Clinics, Other End Users 4) By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Applications

Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. The main types of tumor embolization devices are radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents involve gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) used in the treatment of tumors. The applications involved are cancer tumors and noncancerous tumors that are used by various end-users such as hospitals, cancer treatment centers, intensive care units, and surgical centers. The tumor embolization devices market research report is one of a series of new reports from The Business Research Company that provides tumor embolization devices market statistics, including tumor embolization devices industry global market size, regional shares, competitors with a tumor embolization devices market share, detailed tumor embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor embolization devices industry. This tumor embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tumor embolization devices market grew from $1.44 billion in 2022 to $1.61 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor embolization devices market is expected to grow from $2.5 billion in 2027 at a CAGR of 11.6%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the tumor embolization devices market during the forecast period. According to the American Cancer Society, there were about 1.9 million new cases and 608,570 cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the tumor embolization market over the forthcoming years. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to advanced therapies and advanced therapy medicinal products. These regulations include changes to equipment approval procedures and other aspects. For instance, the United States Food and Drug Administration is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the tumor embolization devices market. Companies in the tumor embolization devices market are increasingly investing in technological advances to provide more efficient devices to consumers. The advances include the emergence of biocompatible, biodegradable, drug-eluting microspheres that provide effective embolization. Bioresorbable microspheres block the blood vessels causing tumors without long-term blockage of the healthy tissue blood vessels. In May 2021, Emboline received an investment of $55 m to develop and launch embolic protection catheters from Matrix Capital Management. In Boston Scientific, a US-based medical device manufacturer, acquired Obsidio Inc. for an undisclosed amount. The acquisition would help Boston Scientific to expand its interventional oncology and embolization portfolio. Obsidio is a US-based developer of Embolization gel. Major players in the tumor embolization devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Sirtex Medical Ltd., Merit Medical, Cook Meidical LLC., BTG PLC., Angiodynamics, and Siemens Healthineers. North America was the largest region in the tumor embolization devices market in 2022. Asia-Pacific was the second largest region in the global tumor embolization devices market. The regions covered in the global tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor embolization devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tumor embolization devices market is segmented - 1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents 2) By Application: Cancer Tumors, Noncancerous Tumors 3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies. The main types of monoclonal antibody therapies in cancer are bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different applications include breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and others, and involve various sectors such as hospitals and clinics, research laboratories, pharmacies, and others. The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer monoclonal antibodies market grew from $56 billion in 2022 to $62.46 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer monoclonal antibodies market is expected to grow from $98.11 billion in 2027 at a CAGR of 12.0%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibody market. The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restraint on the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as the required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to the American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and haematology is about $100,000 higher than that of those used in other disease states. Thus, the high development costs of using these advanced techniques will restrain market growth. Companies in the cancer monoclonal antibody market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licenced from Stanford University. Major players in the cancer monoclonal antibody market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals. North America was the largest region in the cancer monoclonal antibodies market in 2022. The regions covered in the global cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer monoclonal antibodies market is segmented - 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies 2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other Applications 3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Other End Users

Cancer vaccines refer to cancer-treatment vaccinations and medications that aid the body in illness prevention and cancer treatment. They have the power to teach the immune system to recognise and eliminate dangerous microbes and cells. The two main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic vaccinations aid in the recognition of a virus or malignant cell by the immune system. The different types of cancers include prostate, cervical, colorectal, throat, and others, and involve various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vectors, and DNA cancer vaccines. The several sectors include cancer treatment centres and research institutes. The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provide cancer vaccines market statistics, such as cancer vaccines industry global market size, regional shares, competitors with a cancer vaccines market share, detailed cancer vaccines market segments, market trends and opportunities, and any other information you may require to thrive in the cancer vaccines industry. This cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer vaccines market grew from $5.29 billion in 2022 to $6.2 billion in 2023 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer vaccines market is expected to grow from $10.66 billion in 2027 at a CAGR of 14.5%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the cancer vaccine market over the coming years. Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of cancer vaccine manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine, uses a range of techniques and treatments for cancer. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, which is affecting cancer vaccine sales. Also, the global homoeopathic product market is projected to reach $18.6 billion by the end of 2027. This trend is expected to continue during the forecast period and limit the demand for cancer vaccines. Companies in the cancer vaccine market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women, with an estimation of 84% of new cases worldwide. So far, there are 3 HPV vaccines currently available for the prophylaxis of cancer. Two of these will protect against both HPV 16 and HPV 18, which cause 70% of cervical cancer, and the third vaccine prevents 3 more oncogenic HPV types, which further cause 20% of cervical cancers. These three vaccines include Gardasil and Gardasil 9 by Merck and Cervarix by GSK. In May 2020, Merck, a US-based pharmaceutical company, acquired Themis Bioscience for an undisclosed amount. The acquisition is expected to complement Merck's capabilities in the development, manufacturing, and distribution of vaccines. Themis Bioscience is a pharmaceutical company that manufactures vaccines and immune-modulatory therapies developed using the measles virus vector platform, originally based on a vector. Major players in the cancer vaccines market are GlaxoSmithKline, Merck, Aduro Biotech, AstraZeneca PLC., Dendreon, Astellas Pharma Inc., Sanofi Pasteur, Sanpower Group, and CSL Limited. North America was the largest region in the cancer vaccines market in 2022. The regions covered in the global cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer vaccines market consists of sales of Bacillus calmette-guérin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer vaccines market is segmented - 1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines 3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types 4) By End-User: Cancer Treatment Centers, Research Institutes

Cancer clinical decision tools refer to the tools that are developed to help medical practitioners identify suspected cancer signs and symptoms and treat patients effectively. These tools aid in clinical decision-making by assisting GPs in deciding whether to refer or seek additional diagnostic testing in patients suspected of having cancer. The main types of cancer clinical decision tools are risk assessment tools (RAT) and Qcancer. By examining a combination of risk factors, including genetic, environmental, and behavioural risk factors, risk assessment tools make it easier to translate these risk models into estimates of an individual’s likelihood of acquiring certain malignancies. The different sectors include hospitals and clinics. The cancer clinical decision tools market research report is one of a series of new reports from The Business Research Company that provides cancer clinical decision tools market statistics, including cancer clinical decision tools industry global market size, regional shares, competitors with a cancer clinical decision tools market share, detailed cancer clinical decision tools market segments, market trends and opportunities, and any further data you may need to thrive in the cancer clinical decision tools industry. This cancer clinical decision tools market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer clinical decision market grew from $0.4 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer clinical decision market is expected to grow from $0.65 billion in 2027 at a CAGR of 9.9%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision-making tools market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates across the globe will increase the demand for cancer clinical decision tools to make treatment decisions faster, thereby contributing to the market's growth. The breach of patient data and privacy is a major challenge in the market for cancer clinical decision tools. Hackers can get access to data centres through healthcare employees’ emails, leading to a breach of patients' privacy. For instance, in October 2021, according to Fortune, a US-based publishing company specialising in the publication of books, articles, and magazines, the total number of global data breach cases was 1291 in 2021, up from 1108 in 2020. Phishing and ransomware are the major tools used by cybercriminals, and the total number of data breaches is expected to increase to 17% in 2021. The risk of a loss of data and the privacy of patients harms the growth of the market for cancer clinical decision tools. In March 2021, NeoGenomics Laboratories, Inc., a US-based company that provides clinical laboratories, pharmaceutical services, and information services and focuses on cancer genetics diagnostic testing, acquired Trapelo Health, LLC., for an amount of $65 million. Through this acquisition, NeoGenomics would be able to apply precision oncology. In order to help doctors, labs, and payers choose diagnostics and treatments, enhance clinical trial matching, expedite workflow, and enable real-time alignment with the most recent clinical data, the firm offers a first-of-its-kind, interoperable, decision-support platform. The platform makes it easier for patients to access high-quality, medically acceptable therapy alternatives. This acquisition allows NeoGenomics to utilise a single technological platform developed by Trapelo Health that enables real-time, evidence-based decision assistance, treatment selection, and reimbursement assurance for oncologists, giving patients the best chance to cure cancer. Trapelo Health, LLC., is a healthcare technology company specialising in a decision-support platform, order management, and results reporting solution for molecular testing for cancer. Major players in the cancer clinical decision tools market are McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthcare, Elsevier B.V., Macmillan, and National Decision Support Company. North America was the largest region in the cancer clinical decision tools market in 2022. The regions covered in the global cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The market for cancer clinical decision tools consists of sales of risk assessment tools, Q-Cancer tools, and MacMillan’s cancer decision tool. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale, either further along the supply chain or as part of other products. The global cancer clinical decision tools market is segmented - 1) By Type: Risk Assessment Tool (RAT), Qcancer 2) By End-User: Hospital, Clinics

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defences against the disease. Your body's immune system aids in the defence against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others. The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system like human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics. The cancer immunotheraphy market research report is one of a series of new reports from The Business Research Company that provides cancer immunotheraphy market statistics, including cancer immunotheraphy industry global market size, regional shares, competitors with a cancer immunotheraphy market share, detailed cancer immunotheraphy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotheraphy industry. This cancer immunotheraphy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer immunotherapy market size grew from $84.98 billion in 2022 to $95.85 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer immunotherapy market size is expected to grow to $154.42 billion in 2027 at a CAGR of 12.7%. The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, according to the report published by National Cancer Institute (USA), in 2020, cancer was among the leading causes of death worldwide, with an estimated 1,806,590 new cases and 606,520 deaths due to cancer in the United States. By 2040, the number of cancer cases per year is expected to be 29.5 million, with 16.4 million cancer-related deaths. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period. The Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market. There has been a surge of new technologies and various therapies to help the immune system identify and attack tumors using different therapies and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technologies can make a significant difference in cancer treatment and cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had received approval for its Capivasertib in combination with Faslodex. This drug is a cancer immunotherapeutic developed for the treatment of breast cancer and is effective in following recurrence or advancement on or after endocrine therapy in locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2). In August 2021, Bayer AG, a Germany-based pharmaceutical and biotechnology company, acquired Vividion Therapeutics, Inc., for an amount of $1.5 billion. With this acquisition, Bayer increases its drug discovery and research expertise, develops new modalities, new chemoproteomic screening technology, a data portal, and a chemistry library in cancer immunotherapeutics. Vividion Therapeutics, Inc., is a US-based biotechnology company specializing in cutting-edge discovery tools so that cancer and immunological illnesses like cancer can be treated precisely while also gaining access to high-value targets that have previously been unreachable. Major players in the cancer immunotherapy market are Amgen, AstraZeneca, F. Hoffman La-Roche, Bayer AG, Eli Lilly and Company, Pfizer Inc., Merck KGAA, Novartis AG., GlaxoSmithKline PLC, Janssen Global Services, OSE Immunotherapeutics, Celgene Corporation, Seattle Genetics Inc., AMAL Therapeutics, and Bluebird bio. North America was the largest region in the cancer immunotherapy market in 2022 and is also expected to be the fastest-growing region in the forecast period. The regions covered in cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer immunotherapy market is segmented - 1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy 2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma 3) By End User: Hospitals, Cancer Research Centers, Clinics